| ²é¿´: 329 | »Ø¸´: 0 | ||
zhaoman0809гæ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÖúÓ¢ÎÄÎÄÏ×·Òë
|
| ÇóÖúÄܰï·ÒëÏÂÏÂÃæÕâÆªÓ¢ÎÄÎÄÏ×£¡Óм±Óã¡Ð»Ð»£¡ |
» ±¾Ìû¸½¼þ×ÊÔ´Áбí
-
»¶Ó¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com - ¸½¼þ 1 : TMP21TransmembraneDomainRegulates¦Ã-SecretaseCleavage.pdf
2012-11-14 13:34:05, 2.22 M
» ²ÂÄãϲ»¶
Wnt-C59£ºPORCN°ÐÏò»¯Ñ§Ì½Õ룬WntÐźÅͨ·×è¶Ï»úÖÆÓë¿ÆÑÐÓ¦ÓÃÈ«½âÎö
ÒѾÓÐ0È˻ظ´
Fexaramine£º³¦µÀÏÞÖÆÐÔFXR»¯Ñ§Ì½Õ룬½á¹¹ÌØÕ÷ÓëÐźÅͨ·Ñо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ214È˻ظ´
NVS-STG2£º°ÐÏòSTING¿çĤÓòµÄ·Ö×Ó½ºÀ༤¶¯¼Á£¬½á¹¹ÌØÕ÷Óë¹Ñ¾Û»¯»úÖÆÑо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
DOTA-GPC3ëÄ£¨CAS 3066439-94-6£©£ºË«¹¦ÄÜ·Ö×Ó̽ÕëǰÌåµÄ½á¹¹ÌØÕ÷Óë±ê¼ÇÓ¦ÓýâÎö
ÒѾÓÐ0È˻ظ´
¿ÆÑÐÓà TLR7/8 Ë«¼¤¶¯¼ÁÔõôѡ£¿ÏÖ»õÓëÖÊ¿ØÒªµã
ÒѾÓÐ0È˻ظ´
SEL120-34A HCl£ºCDK8/CDK19¸ßÑ¡ÔñÐÔ¼¤Ã¸ÒÖÖÆ¼Á
ÒѾÓÐ0È˻ظ´
ÇâÑõ»¯¼Ø»î»¯²Ù×÷
ÒѾÓÐ18È˻ظ´
É¢½ð
ÒѾÓÐ68È˻ظ´
ÉúÎïÖʳ¬¼¶µçÈÝÆ÷
ÒѾÓÐ0È˻ظ´










»Ø¸´´ËÂ¥
28